At present , laboratory medicine has become one of the fastest growing subjects in the field of medicine.The development of laboratory medicine directly led to the improvement of diagnosis and the increase of test methods in clinic .The data of project applications and grants of the National Natural Science Foundation of China in the field of laboratory medicine from 2014 to 2017 were reviewed and summarized.The future prospect was also analyzed to provide references for related researchers in this field .

Objective To explore the characteristics and efficacy of manual treatment for postpartum hypogalactia.Methods To retrieve the CNKI from 2007 to 2017 on the massage and manual treatment for postpartum hypogalactia,and analyze its syndrome differentiation,acupoint selection,manipulation rules,treatment frequency,treatment courses and clinical efficacy.Results Among the 83 articles included,the massage therapy for postpartum hypogalactia were based on the diseases and syndromes,and the selection of acupoints was diverse and combined with local and distance such as Danzhong (CV 17),Rugen (ST 18),Shaoze (SI 1),Zusanli (ST 36),Pishu (BL 20).The therapy were rich in techniques which often use acupoint stimulation and manipulation.Conclusions Tuina therapy for postpartum hypogalactia is widely used with safety and reliablility.But the operational procedures and efficacy standards need to be further standardized.

Claudins (CLDN) 18.2, a member of transmembrane protein family, belongs to a subtype of the tight junction protein family. It is highly expressed in a variety of tumor tissues of digestive system, but rarely expressed in normal tissues. Therefore, it is a potential new target for targeted therapy and immunotherapy. Abnormal expression of CLDN18.2 can damage epithelial cells and endothelial cells, which plays an important role in the invasion and metastasis of a variety of malignant tumors of epithelial origin. The expression level of CLDN18.2 is significantly increased in gastric cancer, esophageal cancer and other malignant tumors of digestive tract, which indicates the possible key role of CLDN18.2 in the progression of tumors. Therefore, CLDN18.2 can be used as potential therapeutic targets. This article reviews the role of CLDN18.2 in basic research and clinical applications of digestive tumors.